Idexx Laboratories, Inc [IDXX] stock is trading at $459.78, down -0.17%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IDXX shares have gain 8.94% over the last week, with a monthly amount glided 7.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Idexx Laboratories, Inc [NASDAQ: IDXX] stock has seen the most recent analyst activity on December 02, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $500. Previously, BTIG Research started tracking the stock with Buy rating on July 25, 2024, and set its price target to $580. On January 30, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $525 on the stock. Exane BNP Paribas started tracking the stock assigning a Outperform rating and suggested a price target of $602 on December 07, 2023. Cleveland Research upgraded its rating to a Buy. Atlantic Equities downgraded its rating to Neutral for this stock on August 02, 2023, but kept the price target unchanged to $610. In a note dated July 25, 2022, Stifel downgraded an Hold rating on this stock but restated the target price of $415.
Idexx Laboratories, Inc [IDXX] stock has fluctuated between $398.50 and $583.39 over the past year. Currently, Wall Street analysts expect the stock to reach $479.75 within the next 12 months. Idexx Laboratories, Inc [NASDAQ: IDXX] shares were valued at $459.78 at the most recent close of the market. An investor can expect a potential return of 4.34% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
Idexx Laboratories, Inc [NASDAQ:IDXX] reported sales of 3.90B for the trailing twelve months, which represents a growth of 5.84%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.27, Equity is 0.56 and Total Capital is 0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 455.15 points at the first support level, and at 450.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 466.60, and for the 2nd resistance point, it is at 473.43.
Ratios To Look Out For
For context, Idexx Laboratories, Inc’s Current Ratio is 1.31. Further, the Quick Ratio stands at 0.95, while the Cash Ratio is 0.27. Considering the valuation of this stock, the price to sales ratio is 9.66, the price to book ratio is 23.31 and price to earnings (TTM) ratio is 43.10.
Transactions by insiders
Recent insider trading involved Margaret Anne Szostak, Director, that happened on Feb 07 ’25 when 3000.0 shares were purchased. Director, Vandebroek Sophie V. completed a deal on Nov 27 ’24 to sell 344.0 shares. Meanwhile, Director Vandebroek Sophie V. bought 344.0 shares on Nov 27 ’24.
